Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer

NCT02785250 is registered in ClinicalTrials.gov with ImmunoVaccine Technologies, Inc. (IMV Inc.) as lead sponsor.

NCT NCT02785250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02785250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 30, 2016
Completion date
May 31, 2025
Enrollment
85 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, recurrent peritoneal cancer